Mammoth Biosciences

Mammoth Biosciences

Mammoth Biosciences

The world's first CRISPRenabled platform for disease detection.
Founded
2017
Raised
$68M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$45,000,000
Venture capital (Series B) - 2020
Mayfield Fund Decheng Capital Plum Alley +6
$23,000,000
Venture capital (Series A) - 2018
NFX Guild 8VC Mayfield
Team Size
1–10
Employees
Forbes Tech

Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein

TechCrunch

Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH fundings through RADx program

TechCrunch

Mammoth Biosciences receives first peer-reviewed validation of CRISPR-based COVID-19 test

$45,000,000 Venture capital (Series B)
FinSMEs , MedCity News

Mammoth Biosciences Raises $45M in Series B Funding Round

TechCrunch

Mammoth Biosciences aims to be Illumina for the gene editing generation

$23,000,000 Venture capital (Series A)
FinSMEs , PE HUB

CRISPR-Based Disease Detection Platform Mammoth Biosciences Raises $23M

Funding
TechCrunch

Mammoth Biosciences raises $23 million for its CRISPR-based disease detection engine

Science Funding
TechCrunch

Mammoth Biosciences launches a CRISPR-powered search engine for disease detection

Science